Abstract
Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therapy has a narrow therapeutic window for optimal balance of risk and benefit, which requires regular assessment of the international normalized ratio (INR) to monitor coagulation. A quest for safer, more effective therapies that do not need monitoring has led to the development of dabigatran, rivaroxaban, and apixaban. In this article, we review these newer antithrombotic agents and discuss role of these drugs in clinical practice.
Keywords: Atrial fibrillation, Antithrombotic, Bleeding, Thromboembolism, Stroke, Clotting factors, embolism, antagonists, intracranial hemorrhage
Cardiovascular & Hematological Disorders-Drug Targets
Title:Antithrombotic Options for Atrial Fibrillation in 2012
Volume: 12 Issue: 1
Author(s): Jennifer Rude, Karla Quevedo, Lissette Rodriguez de Armas and Debabrata Mukherjee
Affiliation:
Keywords: Atrial fibrillation, Antithrombotic, Bleeding, Thromboembolism, Stroke, Clotting factors, embolism, antagonists, intracranial hemorrhage
Abstract: Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therapy has a narrow therapeutic window for optimal balance of risk and benefit, which requires regular assessment of the international normalized ratio (INR) to monitor coagulation. A quest for safer, more effective therapies that do not need monitoring has led to the development of dabigatran, rivaroxaban, and apixaban. In this article, we review these newer antithrombotic agents and discuss role of these drugs in clinical practice.
Export Options
About this article
Cite this article as:
Rude Jennifer, Quevedo Karla, Rodriguez de Armas Lissette and Mukherjee Debabrata, Antithrombotic Options for Atrial Fibrillation in 2012, Cardiovascular & Hematological Disorders-Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187152912801823110
DOI https://dx.doi.org/10.2174/187152912801823110 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alpha 1 Anti-Trypsin: One Protein, Many Functions
Current Molecular Medicine Utility of γH2AX as a Molecular Marker of DNA Double-Strand Breaks in Nuclear Medicine: Applications to Radionuclide Therapy Employing Auger Electron-Emitting Isotopes
Current Radiopharmaceuticals Endothelin Receptor Antagonists as Disease Modifiers in Systemic Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis
Current Diabetes Reviews Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Transfusion-related Acute Lung Injury: An Overview
Current Pharmaceutical Design The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews Editorial (Thematic Issue: Interventional Management of Hypertension and Cardiovascular Disease: The Beginning of a New Era?)
Current Vascular Pharmacology Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Pharmacological Inhibition of MMP3 as a Potential Therapeutic Option for COVID-19 Associated Acute Respiratory Distress Syndrome
Infectious Disorders - Drug Targets Apoptosis in Atherosclerosis: A Mini-Review
Mini-Reviews in Medicinal Chemistry Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome
Current Pharmaceutical Design The Relevance of Drug Volume of Distribution in Antibiotic Dosing
Current Pharmaceutical Biotechnology Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Patent Selections
Recent Patents on Medical Imaging Diabetes and the Chronic Care Model: A Review
Current Diabetes Reviews Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders Structure-Activity Relationship and Efficacy of Pyridinium Oximes in the Treatment of Poisoning with Organophosphorus Compounds: A Review of Recent Data
Current Topics in Medicinal Chemistry